Drug Profile
Vandetanib-eluting beads - BTG
Alternative Names: Vandetanib-eluting radiopaque beadsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator BTG; Centre Hospitalier Universitaire Vaudois
- Developer BTG; UCL Cancer Institute
- Class Antineoplastics; Bromobenzenes; Fluorobenzenes; Piperidines; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Liver cancer
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for clinical-Phase-Unknown development in Colorectal-cancer(Metastatic disease) in United Kingdom (Intra-arterial)
- 28 Nov 2020 No recent reports of development identified for clinical-Phase-Unknown development in Liver-cancer(Second-line therapy or greater) in United Kingdom (Intra-arterial)
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation